A Case Report and Literature Review of A Child with Refractory Anti-N-methyl-D-aspartate Receptor Encephalitis Treated with Tocilizumab
10.13748/j.cnki.issn1007-7693.20232480
- VernacularTitle:托珠单抗治疗1例儿童难治性抗N-甲基-D-天冬氨酸受体脑炎的病例报告及文献复习
- Author:
Weiqin ZHANG
1
;
Huawei ZHAO
2
;
Zhenzhen WANG
1
;
Feng GAO
1
;
Zhefeng YUAN
1
Author Information
1. Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Department of Neurology
2. Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Department of Pharmacy, Hangzhou 310052, China
- Publication Type:Journal Article
- Keywords:
tocilizumab；children ； refractory；anti-NMDAR encephalitis
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(6):834-838
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To explore the safety and efficacy of tocilizumab in the treatment of refractory anti-N-methyl-D-aspartate receptor encephalitis in children, and to provide reference for the treatment of this disease.
METHODS
The clinical manifestations, diagnosis and treatment, safety and efficacy of tocilizumab in a case of refractory anti-NMDAR encephalitis in Children’s Hospital, Zhejiang University School of Medicine were analyzed retrospectively, and the relevant literature was reviewed.
RESULTS
The clinical symptoms of the patient were not improved after 2 doses of methylprednisolone, immunoglobulin and 6 doses of rituximab. After 6 doses of tocilizumab, the modified Rankin scale(mRS) score was improved without adverse reactions.
CONCLUSION
Tocilizumab, as a escalation second-line immunotherapy, is effective and well tolerated in the treatment of refractory anti-NMDAR encephalitis. It is one of the potential therapeutic means.
